TOTAL: $40.39M
Year to Date: $409.67M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Acrux Ltd.
(Australia;
ASX:ACR)

Elanco Animal Health (unit of Eli Lilly and Co.)

A$0.5 ($0.39)

Milestone payment

Triggered by the the granting of a patent in Europe covering Acrux's drug delivery technology; Elanco has rights in animal health applications (5/8)

Arena
Pharmaceuticals
Inc.
(ARNA)

Merck & Co. Inc.

$4

Milestone payment

Triggered by Merck's initiation of a Phase II trial of MK-0354, an Arena- discovered candi-date being developed for treating atherosclerosis and related disorders (5/18)

Emisphere
Technologies
Inc.
(EMIS)

Novartis Pharma AG (Switzerland)

$5

Milestone payment

Triggered by Novartis' decision to initiate development of an oral human growth hormone product using Emisphere's eligen delivery technology (5/1)

Flamel
Technologies
SA
(France;
FLML)

GlaxoSmithKline plc (UK)

$1

Milestone payment

Triggered by successful completion of activities related to the manufacturing process for Coreg CR microparticles, under their December 2004 supply agreement (5/19)

Maxygen Inc.
(MAXY)

F. Hoffmann-La Roche Ltd. (Switzerland)

$5

Milestone payment

The preclinical milestone was triggered by Maxygen's development of a manufacturing process for Factor VIIa product candidates (5/9)

Metabolex
Inc.*

Astellas Pharma Inc. (Japan)

ND

Milestone payments

Payments were triggered by Astellas' initiation of a high-throughput screen on a previously selected target from their collaboration, and its choice of an additional target for screening (5/25)

Rigel
Pharmaceuticals
Inc.
(RIGL)

Pfizer Inc.

$5

Milestone payment

Triggered by Pfizer's selection of R343 for advanced preclinical development in allergic asthma, from their 2005 collaboration on syk kinase inhibitors (5/17)

SuperGen
Inc.
(SUPG)

MGI Pharma Inc. (MOGN)

$20

Milestone payment

Triggered by MGI's first commercial shipment of the recently approved drug Dacogen (5/26)

TransPharma-
Medical Ltd.*
(Israel)

Teva Pharmaceuticals Industries Ltd. (Israel)

ND

Milestone payment

Triggered by successful completion of the first clinical trials from their deal dating back to 2004 (5/1)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company.

Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed.

ASX = Australian Stock Exchange.

No Comments